Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2021

View Archived Issues

Enrollment begins in phase I/II study of etrumadenant in metastatic colorectal cancer

Brain-penetrant ALK inhibitor NUV-655 active against treatment-resistant mutations

Phase I trials planned for new PARP1/2 inhibitor RP-12146

AP-101 appears to be safe and well tolerated in phase I study in ALS patients

Aurigene CD73 inhibitor AU-21218 inhibits tumor growth in vivo

First patients dosed in SAVE 1 phase IIa study ATI-2173

FDA clears IND application for APB-102 as treatment of SOD1 ALS

FDA grants IND approval for Zofin in the treatment of osteoarthritis

Dosing starts in phase I study of AL-102 in combination with WVT-078 in patients with MM

AUT-00206 improves auditory information processing in patients with schizophrenia

Novartis and Gilead Sciences patent compounds for herpes virus infections

Nirogyone Therapeutics discloses MCT inhibitors

Boragen identifies new JAK inhibitors

Innovo Therapeutics synthesizes new immunomodulators

Sangamo Therapeutics presents new compounds for prion diseases

UCB-0599 shows safety in older individuals with PD with age-related comorbidities

Targeting the adenosine pathway for cancer immunotherapy

SAB-185 studied as part of ACTIV-2 trial for treatment of COVID-19

AN-3025: an anti-TNFR2 antibody for cancer immunotherapy

Valneva begins pivotal trial of COVID-19 vaccine candidate VLA-2001

Treatment begins in clinical trial of GNT-0004 gene therapy for Duchenne muscular dystrophy

Bharat reports second interim analysis of phase III study of Covaxin COVID-19 vaccine candidate

PCSK9 affects antitumor immunity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...